

REMARKS


It is believed that the foregoing amendment addresses points 1 and 2 of the Quayle action, the only points open.

With respect to the first paragraph of the action, Mr. Hanson also requested that the Office Action explain why this application, which is a divisional, would have a specification differing from its parent, grandparent, great grandparent, and great great grandparent specifications. The Examiner did not comply.

Allowance is believed proper and is urged.

Respectfully submitted,

FULBRIGHT & JAWORSKI, L.L.P.

By: 

Norman D. Hanson, Esq.

Registration No. 30,946

666 Fifth Avenue

New York, New York 10103-3198

(212) 318-3000

(212) 318-3400 (fax)



**Revised section of Page 4, lines 31-35:**

Figure 1 shows the alignment of the serine/threonine (S/T) kinase domain (I-VIII) of related receptors from transmembrane proteins, including embodiments of the present invention. The nomenclature of the subdomains is accordingly to Hanks et al. (1988). The amino acid sequences are set forth at amino acids 246-427 of SEQ ID NO: 32, 216-391 of SEQ ID NO: 31, 194-368 of SEQ ID NO: 30, and 1-178 of SEQ ID NO: 33.

**Revised section of Page 5, lines 3-8:**

Figure 3 is a comparison of the amino-acid sequences of human activin type II receptor (Act R-II), mouse activin type IIB receptor (Act R-IIB), human TGF- $\beta$  type II receptor (T $\beta$ R-II), human TGF- $\beta$  type I receptor (ALK-5), human activin receptor type IA (ALK-2), and type IB (ALK-4), ALKs 1 & 3 and mouse ALK-6. See SEQ ID NOS: 30, 31, 32, 10, 2, 4, 6, 8, and 18.

**Revised section of Page 5, lines 12-14:**

Figure 5 shows the sequence alignment of the cysteine-rich domains of the ALKs, T $\beta$ R-II, Act R-II, Act R-IIB and daf-1 receptors. See positions 34-95 of SEQ ID NO: 2, 35-99 of SEQ ID NO: 4, 61-130 of SEQ ID NO: 6, 34-100 of SEQ ID NO: 8, 36-106 of SEQ ID NO: 10, 30-110 of SEQ ID NO: 30, 29-109 of SEQ ID NO: 31, 51-143 of SEQ ID NO: 32, and 5-101 of SEQ ID NO: 34.